Analysis of the Restriction of Vancomycin Use in Hospitals Before, During and After the Implementation of the Antimicrobial Resistance Control Program (ARCP)

Eustachius Hagni Wardoyo, Didit Yudhanto, I Gede Yasa Asmara, Claresta Salsabila, Ajeng Retno


Background: A policy restricting the use of vancomycin was a pilot project for the implementation of the Antimicrobial Resistance Control Program (ARCP) in RSUD Nusa Tenggara Barat in 2018. There were three phases of the ARCP in hospitals, namely preparation, execution, and monitoring. This research aimed to evaluate the quality of vancomycin prescribing before, during, and after the implementation of ARCP in 2017–2019. Method: Descriptive analysis was conducted of all the vancomycin prescriptions before, during, and after the implementation of ARCP in 2018. All medical records of cases requiring vancomycin prescriptions during the research period was evaluated: patient characteristics, culture test results, and clinical diagnoses. The quality of vancomycin prescriptions, which was expressed as follows: “Vancomycin prescriptions are intended only for infections caused by Gram-positive pathogens, particularly Staphylococcus aureus, that are resistant to methicillin (MRSA), Enterococcus sp (Vancomycin-sensitive enterococci)” was evaluated. Results: There were sixty-one cases of vancomycin prescribing; 21 female and 40 male patients, with a mean age of 23 years (0–82 years). Overall, there were 41 positive cultures, 5 negative cultures, and 15 no-cultures. The diagnoses were moderate to severe infections: sepsis, pneumonia, post-surgery infections, CNS infections, low birth weight, septic shocks, and chronic obstructive lung diseases. The urinary tract infection was present as a mild infection. The prescription quality indicators ‘vancomycin is prescribed only for moderate to severe infections’ and ‘prescribed only for Gram-positive pathogens’ altogether increased. Conclusion: There was improvement in the vancomycin prescription quality after the implementation of the vancomycin restriction policy.


Antimicrobial Resistance Control Program, vancomycin restriction policy

Full Text:



Parathon H, Kuntaman K, Widiastoety TH, Muliawan BT, Karuniawati A, Qibtiyah M, et al. Progress towards antimicrobial resistance containment and control in Indonesia. BMJ. 2017;

Hadi U, Kuntaman K, Qiptiyah M, Paraton H. Problem of antibiotic use and antimicrobial resistance in indonesia: are we really making progress? Indones J Trop Infect Dis. 2013;

Lestari SE. Perkembangan PPRA. Semarang; 2018.

Kemenkes R.I. Peraturan Menteri Kesehatan Nomor 8 Tahun 2015 tentang Program Pengendalian Resistensi Antimikroba di Rumah Sakit. Hukor Depkes RI. 2015;

Kuntaman & Parathon H. Workshop Pengampu PPRA. Denpasar; 2011.

LaPlante, K. L., Cunha, C. B., Morrill, H. J., Rice, L. B EM. Antimicrobial Stewardship: Principles and Practice. USA: CAB International; 2017.

Lee T, Pang S, Abraham S, Coombs GW. Antimicrobial-resistant CC17 Enterococcus faecium: The past, the present and the future. Journal of Global Antimicrobial Resistance. 2019.

Bartoletti M, Giannella M, Tedeschi S, Viale P. Multidrug-Resistant Bacterial Infections in Solid Organ Transplant Candidates and Recipients. Infectious Disease Clinics of North America. 2018.

Webb BJ, Majers J, Healy R, Jones PB, Butler AM, Snow G, et al. Antimicrobial stewardship in a hematological malignancy unit: Carbapenem reduction and decreased vancomycin- resistant enterococcus infection. Clin Infect Dis. 2020;

Sun Y, Huskey RL, Tang L, Inaba H, Gaur AH, Ribeiro R, et al. Adverse effects of intravenous vancomycin-based prophylaxis during therapy for pediatric acute myeloid leukemia. Antimicrob Agents Chemother. 2018;

Ishii H, Hirai K, Sugiyama K, Nakatani E, Kimura M, Itoh K. Validation of a nomogram for achieving target trough concentration of vancomycin: Accuracy in patients with augmented renal function. Ther Drug Monit. 2018;

Kampmeier S, Kossow A, Clausen LM, Knaack D, Ertmer C, Gottschalk A, et al. Hospital acquired vancomycin resistant enterococci in surgical intensive care patients - a prospective longitudinal study. Antimicrob Resist Infect Control. 2018;

Monteiro JF, Hahn SR, Gonçalves J, Fresco P. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect. 2018;

Zlatian O, Balasoiu AT, Balasoiu M, Cristea O, Docea AO, Mitrut R, et al. Antimicrobial resistance in bacterial pathogens among hospitalised patients with severe invasive infections. Exp Ther Med. 2018;

Young BC, Wu CH, Gordon NC, Cole K, Price JR, Liu E, et al. Severe infections emerge from commensal bacteria by adaptive evolution. Elife. 2017;

MT H, DC A, NP P, MK L, CJ D. Unnecessary use of antimicrobials in hospitalized patients: Current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med. 2003;

Vogtländer NPJ, Van Kasteren MEE, Natsch S, Kullberg BJ, Hekster YA, Van Der Meer JWM. Improving the process of antibiotic therapy in daily practice: Interventions to optimize timing, dosage adjustment to renal function, and switch therapy. Arch Intern Med. 2004;



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The Indonesian Journal of Infectious Disese (IJID) has been covered by these following indexing services.



Secretariat Address :

Research Instalation

Sulianti Saroso Infectious Disease Hospital

Jl. Baru Sunter Permai Raya, Jakarta Utara 143040

Telp : (021) 6506559  ext 3119


Email :